224 related articles for article (PubMed ID: 17062712)
21. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
Abe M
Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
[TBL] [Abstract][Full Text] [Related]
22. Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.
Pearse RN
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6274s-6278s. PubMed ID: 17062713
[TBL] [Abstract][Full Text] [Related]
23. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
24. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
[TBL] [Abstract][Full Text] [Related]
25. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
26. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma.
Ehrlich LA; Roodman GD
Immunol Rev; 2005 Dec; 208():252-66. PubMed ID: 16313353
[TBL] [Abstract][Full Text] [Related]
27. Treatment for myeloma bone disease.
Yeh HS; Berenson JR
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6279s-6284s. PubMed ID: 17062714
[TBL] [Abstract][Full Text] [Related]
28. [Research on mechanism underlying bone damage in myeloma--review].
Zhou LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1340-4. PubMed ID: 18088497
[TBL] [Abstract][Full Text] [Related]
29. The mechanism of osteoclast differentiation induced by IL-1.
Kim JH; Jin HM; Kim K; Song I; Youn BU; Matsuo K; Kim N
J Immunol; 2009 Aug; 183(3):1862-70. PubMed ID: 19587010
[TBL] [Abstract][Full Text] [Related]
30. Myeloma bone disease.
Sezer O
Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
[TBL] [Abstract][Full Text] [Related]
31. Myeloma bone disease: pathogenetic mechanisms and clinical assessment.
Silvestris F; Lombardi L; De Matteo M; Bruno A; Dammacco F
Leuk Res; 2007 Feb; 31(2):129-38. PubMed ID: 16764925
[TBL] [Abstract][Full Text] [Related]
32. Myeloma bone disease: pathogenesis, current treatments and future targets.
Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
[TBL] [Abstract][Full Text] [Related]
33. Role of the microenvironment in multiple myeloma bone disease.
Huston A; Roodman GD
Future Oncol; 2006 Jun; 2(3):371-8. PubMed ID: 16787117
[TBL] [Abstract][Full Text] [Related]
34. The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3.
Brunetti G; Oranger A; Mori G; Centonze M; Colaianni G; Rizzi R; Liso V; Zallone A; Grano M; Colucci S
Ann N Y Acad Sci; 2010 Mar; 1192():298-302. PubMed ID: 20392250
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of interleukin-6 gene expression in the bone marrow of patients with multiple myeloma.
Iwasaki T; Hamano T; Ogata A; Kakishita E
Int J Hematol; 1999 Oct; 70(3):163-8. PubMed ID: 10561908
[TBL] [Abstract][Full Text] [Related]
36. [Bone disease in multiple myeloma].
Irisawa H
Nihon Rinsho; 2015 Jan; 73(1):42-6. PubMed ID: 25626302
[TBL] [Abstract][Full Text] [Related]
37. Bone disease in multiple myeloma.
Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
Med Oncol; 2006; 23(4):431-41. PubMed ID: 17303901
[TBL] [Abstract][Full Text] [Related]
38. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
[TBL] [Abstract][Full Text] [Related]
39. Advances in the biology and treatment of bone disease in multiple myeloma.
Raje N; Roodman GD
Clin Cancer Res; 2011 Mar; 17(6):1278-86. PubMed ID: 21411443
[TBL] [Abstract][Full Text] [Related]
40. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]